Loading...
•
Jun 30, 2023
Essa Pharma Q3 2023 Earnings Report
Essa Pharma reported financial results for the fiscal third quarter ended June 30, 2023 and provided a corporate update.
Key Takeaways
ESSA Pharma reported its financial results for the third quarter ended June 30, 2023. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.
Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) is expected to complete in the third calendar quarter of 2023.
A randomized Phase 2 part of the study is expected to be initiated after completing Phase 1.
ESSA entered into a clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate).
Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients is ongoing.
Essa Pharma
Essa Pharma
Forward Guidance
ESSA Pharma's forward-looking statements include the completion of the Phase 1 combination study with enzalutamide, initiation of the randomized Phase 2 part of the study, and the Company’s expected cash runway into 2025.
Positive Outlook
- Completion of the Phase 1 combination study with enzalutamide.
- Initiation of the randomized Phase 2 part of the study.
- Enrollment in the monotherapy and combination studies.
- Assessment of anti-tumor activity in the Phase 2 combination study.
- The Company’s expected cash runway into 2025.
Challenges Ahead
- Risks associated with obtaining positive results of clinical trials.
- Risks associated with obtaining necessary regulatory approvals.
- General business, market and economic conditions.
- Uncertainties in medical, scientific, business, economic, competitive, political and social factors.
- Potential differences between actual results and those expressed or implied in forward-looking statements.